Adamax

Adamax is a modified version of Semax with N-acetylation and C-terminal amidation. These modifications are intended to enhance stability and half-life compared to native Semax. Very limited clinical data.

PubMed results: 36 · Human studies: 11 · Animal studies: 11

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

Doses studied in published research. Information presented for research purposes only, not a recommendation for human use.

• Intranasal — standard range No established dosing, Not established. Semax-class research historically uses intranasal delivery; Adamax-specific human dose-ranging is not published. Research-chemical and community protocols are anecdotal and should not be treated as clinical standards.
• Subcutaneous — standard range No established dosing, Not established. No controlled human protocol for Adamax SC dosing. Related N-acetyl Semax amidate research notes discuss multi-day intranasal schedules; these are not Adamax trial data.

Not established in humans (theoretical confidence)

Adamantane-modified N-acetyl Semax amidate intended to improve enzymatic stability vs native Semax (parent peptide plasma half-life typically reported in tens of minutes). No peer-reviewed human PK study publishes a numeric Adamax half-life.

• Enhanced peptide stability versus Semax (Theoretical): N-acetylation and C-terminal amidation on Adamax are designed to reduce proteolytic degradation and extend half-life relative to native Semax, based on standard peptide-modification principles.
• Neurotrophic and cognitive research interest (Limited): As a stabilized Semax analog, Adamax is discussed in research contexts overlapping ACTH 4-10 fragment and BDNF-related pathways, though dedicated clinical datasets for Adamax remain very limited.
• Nootropic analog research (Limited): Research interest centers on cognitive and neuroprotective endpoints extrapolated from Semax literature rather than large Adamax-specific randomized trials.

• Limited documented human adverse events — Mild, Not established. Published human safety data specific to Adamax are scarce; adverse-effect frequency is not established in peer-reviewed clinical literature.
• Nasal or local irritation (if studied intranasally) — Mild, Anecdotal. By analogy to related ACTH-fragment research peptides sometimes studied via mucosal routes, mild local irritation has been discussed anecdotally rather than in robust trials.

• Known hypersensitivity to Semax-related peptides (Theoretical / Preclinical): Structural relatedness to Semax supports theoretical caution where prior hypersensitivity to ACTH-fragment analogs is documented.
• Pregnancy (Theoretical / Preclinical): Insufficient reproductive safety data for Adamax and related analogs warrant theoretical exclusion from pregnancy research populations.

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water